Sponsor Overview
Explore verified public information about Epizyme, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 2 supporting sources.
Conditions: Epithelioid Sarcoma
Conditions: Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary Hypercalcemic Type, Thoracic Sarcoma, Poorly Differentiated Chordoma, ATRT, Malignant Rhabdoid Tumor of Kidney, Malignant Rhabdoid Tumor of Ovary, Malignant Rhabdoid Tumor, Myxoid Spindle Cell Sarcoma, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Chondrosarcoma, Renal Cell Carcinoma, Myoepithelial Carcinoma, Synovial Sarcoma, Renal Medullary Carcinoma, Malignant Mesothelioma, Desmoplastic Small Round Cell Tumor (DSRCT), Intramedullary Spinal Cord Schwannomatosis
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.